PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 16, 2026Journal of Asthma and Allergy0 citationsOpen Access

Designing an Incremental Egg Oral Immunotherapy Protocol: A Strategic Approach with Safety as a Priority

DMDarin MunyuenAYAraya YuenyongviwatPSPasuree Sangsupawanich

Key Points

  • The study aims to evaluate the safety and efficacy of an incremental egg oral immunotherapy protocol in children with egg allergy.
  • Retrospective review of children aged 1–18 with confirmed egg allergy.
  • Data collection on demographics, specific immunoglobulin E levels, and adverse reactions during therapy.
  • Analysis of safety and efficacy outcomes from the incremental OIT protocol.
  • 14 patients participated, with 4 on egg yolk OIT and 10 on egg white OIT.
  • 43% experienced mild adverse reactions like eczema and itchy throat.
  • No severe reactions were recorded during build-up and maintenance of OIT.
  • 92.9% of patients successfully escalated doses, and 9 reached the target maintenance dose.

Abstract

Purpose: Egg oral immunotherapy (OIT) has demonstrated clinical efficacy; however, 10– 35% of patients discontinue treatment due to severe adverse reactions, particularly during the build-up phase. To improve safety, we developed an incremental egg OIT protocol with gradual dose escalation and an extended build-up period. This study aimed to evaluate the safety and efficacy of this protocol in children with egg allergy. Patients and Methods: We retrospectively reviewed children aged 1– 18 years with hen’s egg allergy confirmed by oral food challenge (OFC) who initiated an incremental egg OIT protocol at Songklanagarind Hospital between August 2023 and March 2025. Demographic characteristics, serum specific immunoglobulin E (sIgE) levels to egg white, egg yolk, and ovomucoid, and adverse reactions during OIT were collected and analyzed. Results: Fourteen patients were included; four underwent egg yolk OIT (EY-OIT) and ten underwent egg white OIT (EW-OIT). The median age was 44.5 months (IQR 31– 63) in the EY-OIT group and 29.5 months (IQR 22.5– 65.25) in the EW-OIT group. Mild adverse reactions occurred in 6 of 14 patients (43%). Reported reactions included active eczema and itchy throat in the EY-OIT group, and perioral erythema, active eczema, and acute urticaria in the EW-OIT group. No severe adverse reactions were observed during the OIT build-up and maintenance phases. Thirteen patients (92.9%) successfully escalated doses according to the protocol, and nine patients reached the target maintenance dose. Conclusion: An incremental egg OIT protocol demonstrated a favorable safety profile in children with egg allergy. No severe adverse reactions occurred during the OIT build-up and maintenance phases, and most patients tolerated gradual dose escalation as planned, supporting the feasibility of this approach in real-world clinical practice. Plain Language Summary: An incremental egg OIT strategy may offer a safer and more feasible approach to desensitization in children with egg allergy, with potential for broader implementation in routine clinical settings. Keywords: egg allergy, egg oral immunotherapy, adverse reaction

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Munyuen et al. (2026) studied this question.

synapsesocial.com/papers/69b79e538166e15b153ab83bhttps://doi.org/10.2147/jaa.s591550
Ask AI
Helpful
Bookmark
Share
View Full Paper